HLA Typing and KIR Ligand Matching of
Donor–Recipient Pairs
High-resolution typing for HLA-A, -B, -C, and
-DRB1 were available for all donor–recipient pairs.
All selected donor–recipient pairs were matched for
HLA-A and -DRB1 alleles. Cases were divided into
those matched for MHC class I alleles (HLA-A, -B,
-C) and those mismatched for HLA-B and/or -C
alleles. KIR ligand status of donor–recipient pairs was
determined from HLA typing; KIR typing was not
performed. Donor–recipient pairs mismatched for the
HLA-B and/or -C loci were subdivided into KIR
ligand–matched, KIR ligand–mismatched in the hostversus-
graft (HVG) direction, and KIR ligand–mismatched
in the GVH direction. Cases with bidirectional
mismatches of KIR ligands were included with
those mismatched in the GVH direction. KIR ligand
mismatch was defined by the absence of donor KIR
ligand class I alleles in the recipient using an algorithm
described by Ruggeri et al [10]. The KIR and MHC
class I ligands considered included KIR2DL1 with
group 2 HLA-C molecules, KIR2DL2/3 with group 1
HLA-C molecules, and KIR3DL1 with HLA-B molecules
carrying the Bw4 epitope as defined by their
predicted amino acid sequences.
HLA Typing and KIR Ligand Matching ofDonor–Recipient PairsHigh-resolution typing for HLA-A, -B, -C, and-DRB1 were available for all donor–recipient pairs.All selected donor–recipient pairs were matched forHLA-A and -DRB1 alleles. Cases were divided intothose matched for MHC class I alleles (HLA-A, -B,-C) and those mismatched for HLA-B and/or -Calleles. KIR ligand status of donor–recipient pairs wasdetermined from HLA typing; KIR typing was notperformed. Donor–recipient pairs mismatched for theHLA-B and/or -C loci were subdivided into KIRligand–matched, KIR ligand–mismatched in the hostversus-graft (HVG) direction, and KIR ligand–mismatchedin the GVH direction. Cases with bidirectionalmismatches of KIR ligands were included withthose mismatched in the GVH direction. KIR ligandmismatch was defined by the absence of donor KIRligand class I alleles in the recipient using an algorithmdescribed by Ruggeri et al [10]. The KIR and MHCclass I ligands considered included KIR2DL1 withgroup 2 HLA-C molecules, KIR2DL2/3 with group 1HLA-C molecules, and KIR3DL1 with HLA-B moleculescarrying the Bw4 epitope as defined by theirpredicted amino acid sequences.
การแปล กรุณารอสักครู่..
